

Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study

R. S. Garfein,* K. Collins,* F. Muñoz,* K. Moser,[†] P. Cerecer-Callu,[‡] F. Raab,[§] P. Rios,[¶] A. Flick,[¶] M. L. Zúñiga,[#] J. Cuevas-Mota,* K. Liang,[†] G. Rangel,** J. L. Burgos,* T. C. Rodwell,* K. Patrick^{§¶}

*Division of Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, [†]San Diego County Health and Human Services Agency, San Diego, California, USA; [‡]Instituto de Servicios de Salud, Tijuana, Baja California, México; [§]Department of Preventive Medicine and Public Health, University of California, San Diego, La Jolla, [¶]Qualcomm Institute, University of California, San Diego, La Jolla, [#]School of Social Work, San Diego State University, San Diego, California, USA; **Comision de Salud Fronteriza, Sección México-Secretaria de Salud, Tijuana, Baja California, México

SUMMARY

BACKGROUND: Although directly observed therapy (DOT) is recommended worldwide for monitoring anti-tuberculosis treatment, transportation and personnel requirements limit its use.

OBJECTIVE: To evaluate the feasibility and acceptability of 'video DOT' (VDOT), which allows patients to record and transmit medication ingestion via videos watched remotely by health care providers to document adherence.

METHODS: We conducted a single-arm trial among tuberculosis (TB) patients in San Diego, California, USA, ($n = 43$) and Tijuana, Mexico ($n = 9$) to represent high- and low-resource settings. Pre-/post-treatment interviews assessed participant characteristics and experiences. Adherence was defined as the proportion of observed doses to expected doses.

RESULTS: The mean age was 37 years (range 18–86),

50% were male, and 88% were non-Caucasian. The mean duration of VDOT use was 5.5 months (range 1–11). Adherence was similar in San Diego (93%) and Tijuana (96%). Compared to time on in-person DOT, 92% preferred VDOT, 81% thought VDOT was more confidential, 89% never/rarely had problems recording videos, and 100% would recommend VDOT to others. Seven (13%) participants were returned to in-person DOT and six (12%) additional participants had their phones lost, broken or stolen.

CONCLUSIONS: VDOT was feasible and acceptable, with high adherence in both high- and low-resource settings. Efficacy and cost-effectiveness studies are needed.

KEY WORDS: US-Mexico border; drug resistance; medication adherence; DOT; cellular phone; mHealth

TUBERCULOSIS (TB) remains a global health threat affecting over two billion people—one third of the world's population—and the third leading cause of deaths due to an infectious disease worldwide.^{1,2} Globally, there are 8.8 million new TB cases per year, resulting in 1.4 million deaths.^{1,2} In 2013, the United States had 9582 new TB cases reported (3.0 cases per 100 000 population).³ While TB incidence in the United States has declined, case rates in San Diego County, CA, USA, were twice the national average, with 206 active TB cases reported in 2013 (6.5/100 000).⁴ Baja California, which shares the busiest land border crossing in the world with California,⁵ has Mexico's highest TB incidence (55.2/100 000), triple the national average.⁴ In San Diego County, 69% of cases in 2011 were foreign-born; 44% were from Mexico.⁶

While TB is curable with antibiotics, poor adher-

ence to the long (≥ 6 months) treatment regimens leads to increased mortality, ongoing disease transmission, and acquired drug resistance. The consequences for patients and the community of poor adherence are so great that the World Health Organization and the US Centers for Disease Control and Prevention recommend directly observed therapy (DOT) for administering anti-tuberculosis treatment,^{7–9} as it is more effective than other interventions for achieving treatment completion.¹⁰

DOT is a patient-centered approach in which patients are observed ingesting each medication dose to ensure adherence and achieve completion. In the United States, DOT workers typically travel to the patient, although in resource-constrained areas, including Mexico, DOT is largely clinic-based. Either way, DOT is labor-intensive, requires transportation, can restrict patients' daily activities, and may be



Figure 1 VDOT system flow diagram. VDOT = video directly observed therapy; SMS = short message service.

impractical for patients living far from health centers. The effectiveness of DOT compared with self-administered therapy has been questioned,^{11,12} possibly due to implementation barriers, suggesting the need for improvements in DOT delivery. In low-/middle-income countries, resource constraints significantly limit DOT use.¹³

To reduce treatment monitoring costs and allow greater patient autonomy, mobile technology is increasingly used to improve patient care and treatment outcomes.^{14–16} Most mobile solutions involve patient reminders, and few actually document medication ingestion.¹⁵ We developed a flexible, low-burden method of providing remote DOT via smartphones called Video DOT (VDOT), which involves patients video-recording themselves taking their medications and transferring the videos using a secure interface to DOT workers for review. We then pilot-tested VDOT for feasibility, acceptability, and potential efficacy in high (San Diego, CA, USA) and low (Tijuana, Baja California, Mexico) resource settings.

METHODS

In 2010–2012, we conducted a single-arm trial among TB patients initially receiving treatment via in-person DOT. Informed by focus groups involving TB patients, care providers, and health officials in San Diego and Tijuana,¹⁷ we developed the VDOT System, and then pilot-tested it in public health departments among newly diagnosed patients with drug-susceptible pulmonary TB.

Eligibility and recruitment

TB Control Program staff in both cities recruited individuals currently receiving treatment for con-

firmed or suspected pulmonary TB. Eligibility criteria included 1) ability to speak English or Spanish, 2) age ≥ 18 years, 3) ≥ 1 month of treatment remaining, and 4) willing and able to provide informed consent. Minors, patients with confirmed or presumed drug-resistant TB, and patients with physical conditions that hindered smartphone use (i.e., severe arthritis, diminished vision) were excluded. Patients could be enrolled in the study any time after their providers had determined that they were tolerating their medications (minimum of 2 weeks), before which the patients received traditional in-person DOT. Patients who met the eligibility criteria were sequentially enrolled. Of the patients approached, two in San Diego and two in Tijuana refused to participate—three noted confidentiality concerns and one did not think he could keep the phone safe.

VDOT procedures

Participants used smartphones provided by the study to record videos of themselves taking each dose of TB medication. Uploaded videos were watched by DOT workers via a secure website to document whether the complete dose was ingested (Figure 1). The VDOT system includes a smartphone application for securely recording, transferring and storing videos, and a web-based client management system used by DOT workers to view and document each event. Daily text message reminders were sent to the participants' phones—one before doses were due and one after the expected video had not been received. The smartphone application automatically sent encrypted, time/date-stamped videos to a secure server via cellular or wifi network. If the service was unavailable, the video remained on the phone until connectivity was restored. For confidentiality, videos could

not be viewed on the phone and they were automatically deleted after they had been sent. The VDOT software application was developed by the investigators exclusively for this study.

All participants received in-person DOT for ≥ 2 weeks before switching to VDOT. DOT workers trained participants on VDOT procedures during routine DOT visits until the participant demonstrated competency (median 2 times; interquartile range 2–5 times). Participants continued on the same schedule as the non-participants for routine clinic visits (i.e., monthly) for medication refills and health status monitoring. Participants were told they could use study the smartphones for TB care purposes, such as calling their doctor, finding TB information and scheduling appointments.

Data collection

The primary outcome measure was adherence rate, calculated as the number of medication doses observed in videos divided by the number of doses expected during the treatment period. If missed or self-administered doses were added to the end of treatment, the number of doses expected was correspondingly increased. The DOT workers in each city checked the VDOT website daily and documented whether 1) a video had been received, and 2) all tablets had been swallowed. If ingestion was not visible or no video was received, participants were contacted to determine problems and were retrained if necessary. Some videos were lost due to technical problems with the newly developed application. As we could not confirm whether those doses were actually ingested, we treated lost videos as missing doses in calculating adherence rates.

Participant characteristics and perceptions of VDOT were obtained through brief (15–20 min) structured interviews conducted by phone or in person before (baseline) and after (follow-up) the participants used VDOT. Baseline interviews included socio-demographics, comfort using smartphones, and concerns about privacy (i.e., TB-related stigma). Binational participants were those who spent ≥ 1 night during the study period across the border from their enrollment city. Alcohol and illicit drug use were also assessed. Follow-up interviews captured participant VDOT experiences, including days needed to learn VDOT process, problems recording videos, confidentiality and satisfaction with VDOT. Change in comfort using smartphones for phone calls, text messaging, taking photos/videos, and accessing the internet were assessed by asking participants to report their level of comfort with each on a 10-point scale (1 = very uncomfortable to 10 = very comfortable) on each interview.

To minimize response bias, the interviews were conducted by research assistants who were not involved in patient care. Participants received

US\$25 in San Diego and 200 pesos (US\$15.25) in Tijuana for completing each interview, but not for using VDOT.

The University of California, San Diego Institutional Review Board, San Diego, CA, USA, and Tijuana General Hospital Bioethics Committee, Tijuana, Mexico, approved the study.

Data analysis

We described the study sample using frequencies (categorical variables), means and ranges (continuous variables). Bivariate analyses were conducted using baseline and follow-up data to identify factors associated with adherence using *t*- or rank-sum tests for continuous variables; categorical variables were examined using χ^2 or Fisher's exact test. Paired *t*-tests were used to assess changes in comfort with smartphones. Multivariable analyses were precluded due to the small sample size. Analyses were conducted using SAS 9.3 (Statistical Analysis System Institute, Cary, NC, USA). Patient comments provided during the follow-up interview are presented to contextualize quantitative findings.

RESULTS

We enrolled 43 participants in San Diego and nine in Tijuana. The overall mean age was 37 years (range 18–86); 50% were male, 88% were non-Caucasian and 51% were Hispanic (Table 1). There were six binational participants in San Diego and none in Tijuana. Participants used VDOT for a mean of 5.5 months (range 1–11), after 2–22 weeks on in-person DOT in San Diego and 2–4 weeks on in-person DOT in Tijuana. Forty-five (87%) participants used VDOT until they completed treatment. Seven participants (13%) were returned to in-person DOT because one had problems operating the smartphone; one, who received assistance from a family member, had to stop when that person moved out; two were non-adherent; one preferred in-person DOT; and two received baseline drug susceptibility testing (DST) results revealing drug-resistant TB after enrollment, rendering them ineligible. All participants who returned to in-person DOT completed treatment successfully. Overall, three (6%) phones were stolen and three (6%) were lost or broken.

Mean adherence was 93% (range 51–100) in San Diego and 96% (range 88–100) in Tijuana (Figure 2). Overall, 5626 videos were received, showing complete doses swallowed (96.0%), partial doses swallowed (0.4%), no pills swallowed (1.5%), and unable to tell if doses were swallowed (2.1%). No sociodemographic or behavioral factors were found to be associated with adherence (data not shown). Throughout treatment, daily text messages were sent to each participant as reminders to take their medication. DOT worker follow-up responses to

Table 1 Baseline characteristics of tuberculosis patients enrolled in VDOT pilot study, 2010–2012

Variables	Total (<i>n</i> = 52) <i>n</i> (%)	San Diego (<i>n</i> = 43) <i>n</i> (%)	Tijuana (<i>n</i> = 9) <i>n</i> (%)
Spends time on both sides of border	6 (11.5)	6 (13.9)	0
Demographics			
Age, years (<i>n</i> = 50)			
Mean ± SD	37.3 ± 17.6	39.0 ± 17.6	28.1 ± 15.3
Range	18–86	18–86	18–65
Sex			
Male	27 (51.9)	23 (53.5)	4 (44.4)
Female	25 (48.1)	20 (46.5)	5 (55.6)
Race/ethnicity (<i>n</i> = 51)			
Asian	13 (25.5)	13 (31.0)	0
African American/Black	3 (5.9)	3 (7.1)	0
Hispanic/Latino	26 (51.0)	17 (40.4)	9 (100)
Pacific Islander/Native Hawaiian	2 (3.9)	2 (4.8)	0
Caucasian/White	6 (11.7)	6 (14.3)	0
Other/mixed race	1 (2.0)	1 (2.4)	0
Highest level of education (<i>n</i> = 49)			
Primary school or below	12 (24.5)	7 (16.7)	5 (71.4)
High school graduate	9 (18.3)	9 (21.4)	0
Some college or above	28 (57.2)	26 (61.9)	2 (28.6)
Housing status (<i>n</i> = 50)			
Lives in own home	35 (70.0)	30 (71.4)	5 (62.5)
Lives in parent's home	8 (16.0)	7 (16.7)	1 (12.5)
Lives in someone else's home	7 (14.0)	5 (11.9)	2 (25.0)
Behavioral risk factors (<i>n</i> = 50)			
Frequency of alcohol use in past year			
Never/rarely	34 (68.0)	28 (66.7)	6 (75.0)
1–2 days/week	12 (24.0)	10 (23.8)	2 (25.0)
3–7 days/week	4 (8.0)	4 (9.5)	0
Smoked cigarettes in past year	7 (14.0)	6 (14.3)	1 (12.5)
Ever used marijuana	13 (26.0)	10 (23.8)	3 (37.5)
Ever used illegal drugs	4 (8.0)	2 (4.8)	2 (25.0)
Ever injected illegal drugs	1 (2.0)	1 (2.3)	0
TB-related stigma concerns (<i>n</i> = 49)			
Felt it is embarrassing to have a DOT worker visit home or work	17 (34.7)	17 (41.5)	0
Worried about family and close friends finding out about TB	17 (34.7)	15 (36.6)	2 (25.0)
Worried about acquaintances, neighbors or coworkers finding out about TB	21 (42.9)	19 (46.3)	2 (25.0)

VDOT = video DOT; SD = standard deviation; TB = tuberculosis; DOT = directly observed therapy.

missed doses included contacting participants to encourage adherence, provide re-training on VDOT procedures, and/or troubleshoot technical problems with recording videos. Advanced age was not a barrier to using VDOT. Older participants in




Figure 2 Tuberculosis medication adherence rates among participants in San Diego, CA, USA, and Tijuana, Baja California, Mexico (*n* = 51).

particular enjoyed learning to use a smartphone and reported feeling that VDOT allowed them to remain in control of their care rather than feeling that their provider did not trust them to take their medications.

Fifty (94%) participants completed the follow-up interviews. Overall, 92% reported never/rarely having problems recording videos, 92% preferred VDOT over in-person DOT, 84% thought VDOT was more confidential and 100% said they would recommend VDOT to others (Table 2). Nearly two thirds of the participants thought the text message reminders were useful. Open-ended questions revealed that participants in both cities thought VDOT was more confidential than in-person DOT. For example, a Tijuana participant said, '[with the VDOT system], I always had the confidence of confidentiality.' A San Diego participant said, 'the phone is a great step for the person to find their own private space...' Furthermore, participants valued the mobility that VDOT gave and the convenience of taking medications on their own schedule. A San Diego participant

Table 2 Follow-up results among tuberculosis patients enrolled in VDOT pilot study, 2010–2012

Variables	Total (<i>n</i> = 52) <i>n</i> (%)	San Diego (<i>n</i> = 41)* <i>n</i> (%)	Tijuana (<i>n</i> = 9) <i>n</i> (%)
VDOT outcomes			
Time spent using VDOT, months (<i>n</i> = 52)			
Mean ± SD	5.5 ± 2.1	5.6 ± 2.2	5.2 ± 1.5
Range	1–11	1–11	2–7
Number of missed doses (<i>n</i> = 52) [†]			
Mean ± SD	2.7 ± 7.0	2.7 ± 7.7	1.9 ± 2.0
Range	0–41	0–41	0–5
Returned to in-person DOT (<i>n</i> = 52)	7 (13.5)	6 (14.0)	1 (11.1)
Phone status at end of study (<i>n</i> = 52)			
Broken/lost	3 (5.8)	2 (4.7)	1 (11.1)
Stolen	3 (5.8)	1 (2.3)	2 (22.2)
VDOT training			
Duration practicing with VDOT before recording videos alone, days (<i>n</i> = 52)			
1	26 (50.0)	25 (58.1)	1 (11.1)
2	6 (11.5)	6 (13.9)	0
3	5 (9.6)	2 (4.7)	3 (33.3)
≥4	12 (23.1)	7 (16.3)	5 (55.6)
Don't know/missing	3 (5.8)	3 (7.0)	0
Found VDOT training process helpful			
Yes	48 (96.0)	39 (95.1)	9 (100)
No	2 (4.0)	2 (4.9)	0
Found VDOT training pamphlet helpful (<i>n</i> = 47)			
Yes	37 (78.7)	30 (79.0)	7 (77.8)
No	10 (21.3)	8 (21.0)	2 (22.2)
Used VDOT training pamphlet when alone (<i>n</i> = 46)			
Yes	20 (43.5)	16 (42.1)	4 (50.0)
No	26 (56.5)	22 (57.0)	4 (50.0)
VDOT technical issues			
Frequency of video recording problems			
≥ half the time	4 (8.0)	3 (7.3)	1 (11.1)
Rarely	27 (54.0)	22 (53.7)	5 (55.6)
Never	19 (38.0)	16 (39.0)	3 (33.3)
Frequency of problems sending videos			
≥ half the time	7 (14.0)	6 (14.6)	1 (11.1)
Rarely	34 (68.0)	28 (68.3)	6 (66.7)
Never	9 (18.0)	7 (17.1)	2 (22.2)
Unable to send video due to poor reception			
≥ half the time	2 (4.0)	2 (4.9)	0
Rarely	17 (34.0)	12 (29.2)	5 (55.6)
Never	31 (62.0)	27 (65.9)	4 (44.4)
Able to send videos when traveling to other cities (<i>n</i> = 47)			
Yes, always	12 (25.5)	10 (26.3)	2 (22.2)
Yes, sometimes	5 (10.6)	4 (10.5)	1 (11.1)
Never tried	30 (63.8)	24 (63.2)	6 (66.7)
VDOT confidentiality			
Confidentiality of VDOT vs. in-person DOT (<i>n</i> = 50)			
More	42 (84.0)	35 (85.4)	7 (77.8)
Less	8 (16.0)	6 (14.6)	2 (22.2)
Failed to record videos because others might see			
No	49 (98.0)	40 (97.6)	9 (100)
Yes	1 (2.0)	1 (2.4)	0
VDOT satisfaction			
If repeat anti-tuberculosis treatment needed, would you choose VDOT or in-person DOT?			
VDOT	46 (92.0)	38 (92.7)	8 (88.9)
No preference	2 (4.0)	2 (4.9)	1 (11.1)
In person	2 (4.0)	1 (2.4)	0
Would you recommend VDOT to other TB patients?			
No	0	0	0
Yes	50 (100)	41 (100)	9 (100)
Found text message reminders helpful (<i>n</i> = 47)			
Yes	30 (63.8)	24 (60.0)	6 (85.7)
No	17 (36.2)	16 (40.0)	1 (14.3)

* Two participants in San Diego did not complete the follow-up interview; thus, overall *n* = 50 for interview questions unless otherwise noted.

[†] Missed doses included failure to take medication and technical problems that made some videos not viewable.

VDOT = video DOT; SD = standard deviation; DOT = directly observed therapy; TB = tuberculosis.




Figure 3 Level of comfort using smartphone functions before and after having tuberculosis treatment monitored using the VDOT System. * Change in comfort score from baseline to follow-up was statistically significant ($P \leq 0.05$). † Measured on a 10-point scale.

stated that, '[VDOT] is a convenient, easy, good system...' Another San Diego participant said, 'the phone was very convenient [for me]. I could take my pills on my own time instead of waiting for someone to watch me.' TB Control Program staff reported that patients had more autonomy and were grateful to have been able to use VDOT. They also reported that the time and travel saved using VDOT allowed them to concentrate on less adherent patients.

While comfort levels using smartphone functions were generally high at baseline (Figure 3), further increases were reported after using VDOT. These increases were statistically significant for making phone calls (+0.77, $P = 0.008$), taking pictures (+1.43, $P = 0.006$), and recording videos (+1.68, $P = 0.009$).

DISCUSSION

VDOT was highly feasible and acceptable among TB patients and providers in both high- and low-resource settings. Most participants preferred VDOT over in-person DOT. Documented observation of nearly all expected doses (mean 93% in San Diego and 96% in Tijuana) was achieved using VDOT. VDOT provided a convenient alternative to in-person DOT without sacrificing treatment adherence because participants could ingest their medications at the time and location of their choosing, without needing to coordinate with a DOT worker. Furthermore, the DOT workers could observe the videos during normal business hours. Adherence was conceivably increased using VDOT because it had fewer barriers to medication-taking than in-person DOT. While the findings from this pilot study might not be generalizable to all TB patients, we enrolled 43 (21%) of San

Diego's 206 annually reported cases and obtained similar results in Tijuana, where nine (1%) of that city's approximately 1000 cases were enrolled. Further studies with less restrictive eligibility criteria in more health care settings are needed to determine which patients are best suited for VDOT.

Inability to monitor medication ingestion while patients are out of the health department's jurisdiction can prolong treatment. VDOT allows observation of all doses, even among mobile patients. For example, six San Diego participants spent part of the week in Mexico, making it impractical for San Diego DOT workers to observe their treatment doses in-person; VDOT enabled the DOT workers to remotely observe the doses being taken while the participants were in Mexico. The participants thus reached the number of observed doses needed to complete treatment sooner than they would have with in-person DOT.

Asynchronous ('store-and-forward') VDOT used in this study may have advantages over synchronous ('video conferencing') forms of remote DOT. For example, in 2004, the San Diego County TB Control Branch pilot tested video conferencing over landline phones to reduce the costs and improve the efficiency of DOT. A DOT worker called patients on weekdays using a video phone and watched them ingest their pills. Among 33 patients over the 9-month trial, the county saved 27 840 miles in travel and 795 staff hours.¹⁸ More recently, health departments have attempted to replicate this process using mobile devices to overcome the problem of tying patients to their homes and the growing trend toward switching from landline to mobile phones. However, patients could still only be observed during business hours, and only when there was a consistent phone

connection. Using asynchronous VDOT, patients can take their medications whenever and wherever they choose, and DOT workers can manage more patients in less time during business hours.

Attention should also be given to those who did not complete treatment on VDOT. Of the seven participants who returned to in-person DOT, two began treatment for presumptive drug-susceptible TB, but were later found to have drug-resistant TB once DST was complete. Two participants, both college students, repeatedly failed to record videos; their adherence improved after returning to in-person DOT. Only one participant requested to return to in-person DOT. After 2 weeks on VDOT, she explained that as a parent of three young children, having a DOT worker visit her home was easier than self-managing her treatment. Another patient with mild cognitive deficiency initially performed VDOT with the assistance of a family member, but when that person moved out the participant was not comfortable recording videos himself. One 83-year-old participant had difficulty using the phone's touchscreen for VDOT because he could not 'feel' a button being pushed. Despite attempts at retraining, the participant was unable to consistently use the application correctly and was returned to in-person DOT. Conversely, an 86-year-old participant used VDOT successfully for 7.6 months with 99% adherence, suggesting that age alone should not disqualify individuals from using VDOT. These findings suggest that VDOT should complement, rather than replace, in-person DOT. Further research is needed to identify patient characteristics for determining which method best suits each patient, and what criteria should be used to withdraw a patient from VDOT.

Some study limitations must be considered. First, as the VDOT application was developed specifically to assess whether this concept was feasible and acceptable, some early participants had lower documented adherence because videos that were lost due to software error were treated as missed doses in calculating adherence rates. Our adherence estimates were therefore conservative. Second, as we were uncertain about how VDOT would work in practice, patients with drug-resistant TB or a history of poor adherence on in-person DOT were ineligible. Patient selection may thus have been biased toward adherent patients, limiting the generalizability of adherence rates to all TB patients; however, such bias is unlikely to have affected satisfaction with VDOT. It should be noted that after gaining experience implementing VDOT for this study, TB Control Program staff reported feeling comfortable with expanding eligibility to include patients with drug-resistant TB and some patients who had low adherence using in-person DOT. Third, this study lacked a control group and we were unable to compare adherence between VDOT

and in-person DOT. As participants were allowed personal use of the study smartphones, providing smartphones could have had an intervention effect; however, providing enablers is not uncommonly practiced by health departments for TB.

CONCLUSIONS

We found VDOT feasible to implement and highly acceptable to patients and providers in both high- and low-resource settings. VDOT effectively captured medication-taking behavior, allowing DOT workers to observe the ingestion of nearly all expected doses. VDOT provides a promising, low-burden alternative to in-person DOT for monitoring adherence to anti-tuberculosis treatment. The reduced burden on patients and providers using VDOT could also make DOT feasible in resource-limited settings where in-person DOT is impractical, as well as allowing TB program staff more time to provide support for less adherent patients. VDOT may also be used to monitor other health conditions where strict medication adherence is essential. Larger, controlled trials are needed to evaluate the efficacy and cost-effectiveness of VDOT for improving and maintaining adherence throughout treatment. Studies in high-burden, low-resource settings are also needed to evaluate the generalizability of VDOT. As mobile technology plays an increasingly important role in health care, VDOT has great potential to expand the coverage of anti-tuberculosis treatment monitoring to more patients worldwide by reducing the burden on both patients and providers, resulting in higher treatment completion rates, fewer new TB cases, and prevention of acquired drug-resistant TB.

Acknowledgements

The authors wish to thank D McIntosh, G Escalante, C Colin, J G Bustamante, R Laniado-Laborin, and M Clark for their efforts and for sharing insights that were crucial for developing the VDOT System. We greatly appreciate M Bulterys' expert editorial review of the manuscript. The authors also thank the study participants for their willingness to use the VDOT System and for the feedback they provided to help improve the system.

This study was funded by grants from the National Institutes of Health (NIH), Bethesda, MD, USA, (R21-AI088326) and the Alliance Healthcare Foundation San Diego, CA, USA. FM was supported by a National Institute on Drug Abuse (Bethesda, MD) grant R01-DA031074-03S1. TCR was supported by a National Institute of Allergy and Infectious Diseases (Bethesda, MD) grant K01-AI083784. JLB was also supported by a National Institute of Mental Health (Bethesda, MD, USA) grant K01-MH095680. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Conflicts of interest: none declared.

References

- 1 World Health Organization. Tuberculosis report 2013. Fact sheet no 104. Geneva, Switzerland: WHO, 2015 <http://www.who.int/mediacentre/factsheets/fs104/en/>. Accessed May 2015.

- 2 Curry International Tuberculosis Center. Drug-resistant tuberculosis: a survival guide for clinicians, 2011. 2nd ed. Oakland, CA, USA: University of California San Francisco, 2011. http://www.currytbcenter.ucsf.edu/drtb/docs/MDRTB_book_2011.pdf. Accessed May 2015.
- 3 Centers for Disease Control and Prevention. Trends in tuberculosis, 2013 factsheet. Atlanta, GA, USA: CDC, 2013. <http://www.cdc.gov/tb/publications/factsheets/statistics/tbtrends.htm>. Accessed May 2015.
- 4 Secretaria de Salud, Jurisdicción Sanitaria No. 2 Tijuana. Programa de Microbacteriosis TB y Lepra 2013. Plan de Acción para el manejo y acceso universal al diagnóstico y tratamiento de la tuberculosis y TB-MFR. Tijuana, Mexico: Jurisdicción de Servicios de Salud No. II Tijuana, 2013.
- 5 US General Services Administration. San Ysidro Land Port of Entry. Washington DC, USA: GSA, 2014. <http://www.gsa.gov/portal/content/104872>. Accessed May 2015.
- 6 County of San Diego Health and Human Services Agency. Tuberculosis and refugee health. San Diego, CA, USA: County of San Diego Health and Human Services Agency, 2013. http://www.sdcountry.ca.gov/hhsa/programs/phs/documents/Factsheet_2013-final_3-13-14.pdf. Accessed May 2015.
- 7 World Health Organization. Global tuberculosis report, 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
- 8 Centers for Disease Control and Prevention. Ten great public health achievements—worldwide, 2001–2010. *MMWR Morb Mortal Wkly Rep* 2011; 60: 814–818.
- 9 World Health Organization. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. WHO/HTM/TB/2006.368. Geneva, Switzerland: WHO, 2006. http://whqlibdoc.who.int/hq/2006/WHO_HTM_STB_2006.368_eng.pdf. Accessed May 2015.
- 10 Chaulk C P, Kazandjian V A. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. *JAMA* 1998; 279: 943–948.
- 11 Pasipanodya J G, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. *Clin Infect Dis* 2013; 57: 21–31.
- 12 Volmink J, Garner P. Directly observed therapy for treating tuberculosis. *Cochrane Database Syst Rev* 2007; (4): CD003343.
- 13 Floyd K, Pantoja A. Financial resources required for tuberculosis control to achieve global targets set for 2015. *Bull World Health Organ* 2008; 86: 568–576.
- 14 World Health Organization. MHealth: new horizons for health through mobile technologies. WHO Global Observatory for eHealth Series Vol 3. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/9789241564250_eng.pdf?ua=1. Accessed May 2015.
- 15 Hoffman J A, Cunningham J R, Suleh A J, et al. Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. *Am J Prev Med* 2010; 39: 78–80.
- 16 Denkinger C M, Grenier J, Stratis A K, Akkihal A, Pant-Pai N, Pai M. Mobile health to improve tuberculosis care and control: a call worth making [Review]. *Int J Tuberc Lung Dis* 2013; 17: 719–727.
- 17 Garfein R S, Patrick K, Moser K, et al. Mobile phone-based video directly observed therapy for tuberculosis. Paper presented at: mHealth Summit, 8–10 November, 2010, Washington, DC, USA.
- 18 DeMaio J, Schwartz L, Cooley P, Tice A. The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project. *Clin Infect Dis* 2001; 33: 2082–2084.

RESUME

CADRE : Le traitement directement observé est recommandé dans le monde entier pour le suivi du traitement de la tuberculose (TB) ; cependant, les problèmes de transport et de personnel requis limitent son utilisation.

OBJECTIF : Evaluer la faisabilité et l'acceptabilité de « vidéo DOT » (VDOT) qui permet aux patients d'enregistrer et de transmettre les vidéos d'ingestion des médicaments qui sont vues à distance par des prestataires de santé pour documenter l'adhésion.

MÉTHODE : Nous avons réalisé un essai parmi des patients TB à San Diego, Californie, Etats Unis ($n=43$) et Tijuana, Mexique ($n=9$) pour être représentatifs à la fois de contextes de ressources élevées et faibles. Des entretiens réalisés avant et après le traitement ont évalué les caractéristiques et les expériences des participants. L'adhésion a été définie comme le rapport des doses observées aux doses attendues.

RÉSULTATS : L'âge moyen a été de 37 ans (fourchette 18–86), 50% étaient des hommes et 88% n'étaient pas blancs. La durée moyenne de l'utilisation de VDOT a été de 5,5 mois (fourchette 1–11). L'adhésion a été similaire à San Diego (93%) et à Tijuana (96%). Comparés aux DOT suivis par une tierce personne, 92% ont préféré le VDOT, 81% ont estimé que le VDOT était plus confidentiel, 89% n'ont jamais/rarement eu des problèmes d'enregistrement des vidéos, et 100% recommanderaient le VDOT aux autres. Au total, sept (13%) participants sont revenus aux DOT par une tierce personne et six (12%) participants ont perdu ou endommagé leur téléphone ou se le sont fait voler.

CONCLUSIONS : Le système VDOT s'est avéré faisable et acceptable avec une adhésion élevée aussi bien dans un contexte de ressources élevées que faibles. Il faut maintenant réaliser des études d'efficacité et de rentabilité.

RESUMEN

MARCO DE REFERENCIA: La terapia directamente observada (DOT) es recomendada mundialmente para el monitoreo de tratamiento de tuberculosis (TB); sin embargo las necesidades de transporte y personal limitan su uso.

OBJETIVO: Evaluar la viabilidad y aceptabilidad de 'Video DOT' (VDOT), el cual permitió a los pacientes grabar y transmitir videos ingiriendo su medicamento, los cuales fueron observados a distancia por los proveedores de salud para documentar la adherencia.

MÉTODOS: Se realizó un estudio de un solo brazo en pacientes con TB en San Diego, CA, Estados Unidos ($n=43$) y Tijuana, México ($n=9$) para representar poblaciones de alto y bajo recursos. Entrevistas antes y después del tratamiento evaluaron características y experiencias de los participantes. La adherencia se definió como la proporción de dosis observadas a dosis esperadas.

RESULTADOS: El edad media fue de 37 años (rango 18–86), 50% eran masculino y 88% eran de etnia no-blanca. La media de tiempo de uso de VDOT fue de 5,5 meses (rango 1–11). La adherencia fue similar en San Diego (93%) y Tijuana (96%). Comparado el tiempo de monitoreo de tratamiento en persona, 92% prefirieron VDOT, 81% pensaron que VDOT proporcionaba mayor confidencialidad, 89% nunca/rara vez tuvieron problemas al grabar videos, y el 100% recomendaría VDOT a otros. En total, siete (13%) de los participantes regresaron a monitoreo de tratamiento en persona y seis (12%) personas distintas perdieron, le robaron o quebraron su teléfono.

CONCLUSIONES: VDOT fue viable y aceptable en poblaciones de alto y bajo recursos. Estudios a futuro de eficacia y costo-efectividad son necesarios.
